Details of the Researcher

PHOTO

Kazuto Shimoya
Section
Graduate School of Pharmaceutical Sciences
Job title
Assistant Professor

Research History 4

  • 2025/04 - Present
    Tohoku University　Graduate School of Pharmaceutical Sciences

  • 2023/04 - 2025/03
    Tottori University　Graduate School of Medical Sciences

  • 2021/04 - 2023/03
    Tottori University　Graduate School of Medical Sciences

  • 2017/04 - 2021/03
    Tottori University　Faculty of Medicine School of Life Sciences

Committee Memberships 1

  • 日本抗体学会 若手研究者の会　実行委員

    2024 - Present

Professional Memberships 3

  • 日本実験動物学会

    2023 - Present

  • 日本抗体学会

    2022 - Present

  • 日本分子生物学会

    2021 - Present

Awards 3

  1. エンカレッジ・ファンド

    2025/02　鳥取大学大学院

  2. 優秀発表賞

    2024/05　公益社団法人日本実験動物学会

  3. エンカレッジ・ファンド

    2024/02　鳥取大学大学院

Papers 5

  1. Preparation of Antibody-Modified mRNA-LNPs via a Combination of Post-Encapsulation and Post-Insertion. International-journal Peer-reviewed

    Yoshie Ri, Shion Oshima, Hiroki Tanaka, Takumi Sugawara, Mizuho Hori, Siril Yves Junior, Yuta Nakai, Kasumi Ito, Kazuto Shimoya, Yu Sakurai, Hidetaka Akita

    ACS applied bio materials　9　(15)　7157-7166　2026/08/03

    DOI： 10.1021/acsabm.6c00925 　

    More details Close

    Using ligand-modified lipid nanoparticles (LNPs) to encapsulate messenger RNA (mRNA) has become an important modality for tissue/organ/cell-specific gene delivery. Modifying mRNA-LNPs either with antibodies or their derivatives (Ab-mRNA-LNPs) has emerged as a promising drug delivery system (DDS) due to its efficacy and target specificity. Manufacturing Ab-mRNA-LNPs, however, involves complex and multi-step procedures that include the encapsulation of mRNA followed by the anchoring of antibodies via polyethylene glycol (PEG) linker-conjugated lipids. In this work, we present a seamless strategy for the production of Ab-mRNA-LNPs by integrating the post-encapsulation of mRNA into mRNA-free LNPs (fLNPs) with a post-insertion of ligand-conjugated PEG-lipid (Lig-PEG-lipid). Using a T-cell-targeting model, we further describe how targeting efficacy is influenced by controlling the surface nature of the Ab-mRNA-LNPs either via the modification of PEG-lipids or by replacing the phospholipids. Modification of the DSPE-PEG-methoxy and employment of either DSPC or DPPC significantly improves the accumulation of Ab-mRNA-LNPs in T cells. These findings highlight the importance of LNP surface engineering.

  2. Rapid immunization and antibody redesign platform discovers broadly neutralizing antibodies against non-immunized SARS-CoV-2 variant. International-journal Peer-reviewed

    Shusei Hamamichi, Narumi Uno, Kazuto Shimoya, Takato Fukushima, Marina Abe, Arata Watanabe, Mizuho Ito, Yuko Wakasa, Yuko Yajima, Rio Suzuki, Natsumi Miyazaki, Akifumi Kamiyama, Kana Uno, Masaharu Hiratsuka, Takashi Moriwaki, Tomokazu Tamura, Kyosuke Kanai, Satoshi Abe, Takasuke Fukuhara, Seiji Kageyama, Masayuki Su'etsugu, Yasuhiro Kazuki, Kazuma Tomizuka

    Molecular therapy : the journal of the American Society of Gene Therapy　2025/10/11

    DOI： 10.1016/j.ymthe.2025.10.020 　

    More details Close

    From COVID-19, we learned valuable lessons related to the development of broadly neutralizing antibodies (bnAbs). Here, we present a discovery platform termed Express Hu-mAb System that integrates a fully human Ab-producing transchromosomic (TC-mAb) mouse, a rapid immunization procedure, and a CHO cell-based mammalian display system (MDS) to generate bnAbs against the non-immunized SARS-CoV-2 variant in 60-90 days. Rapid 30-day immunization of a TC-mAb mouse resulted in increased titers, elevated antibody concentration, and production of anti-serum that neutralized the non-immunized BA.1. Single B cell analysis without using fluorescent antigen probe identified clonotypes that recapitulated immune responses associated with the COVID-19. Importantly, we generated 25 bnAb candidates based on the abundance of sequence reads, determined 14 binders (56%), and identified clonotype 11 as a bnAb that neutralizes the non-immunized BA.5 in 60 days. Next, exploiting a TC-mAb mouse whose anti-serum neutralized only the Wuhan strain, we constructed a chain-shuffled immunoglobulin cDNA library with sufficient diversity of 4.3-6.2 × 104 CHO cells. We then applied the MDS to redesign bnAb candidates, and identified M5419S09Ab01 that neutralizes the BA.5 in 90 days. Taken together, this work demonstrates speed, efficiency, and simplicity of our platform to discover bnAbs against the phylogenetically distinct viral variant with optimal developability and manufacturability.

  3. Mice carrying the full-length human immunoglobulin loci produce antigen-specific human antibodies with the lambda light chain Peer-reviewed

    Kazuto Shimoya, Takashi Moriwaki, Kanako Kazuki, Akane Okada, Shigenori Baba, Yuana Masuda, Satoshi Abe, Yasuhiro Kazuki

    iScience　27　(12)　111258-111258　2024/12

    Publisher: Elsevier BV

    DOI： 10.1016/j.isci.2024.111258 　

    ISSN： 2589-0042

  4. Characterization of immortalized ovarian epithelial cells with BRCA1/2 mutation. Peer-reviewed

    Hiroaki Komatsu, Masayo Okawa, Yasuhiro Kazuki, Kanako Kazuki, Genki Hichiwa, Kazuto Shimoya, Shinya Sato, Fuminori Taniguchi, Mitsuo Oshimura, Tasuku Harada

    Human cell　37　(4)　986-996　2024/07

    DOI： 10.1007/s13577-024-01064-z 　

    More details Close

    We aimed to elucidate the mechanism underlying carcinogenesis by comparing normal and BRCA1/2-mutated ovarian epithelial cells established via Sendai virus-based immortalization. Ovarian epithelial cells (normal epithelium: Ovn; with germline BRCA1 mutation: OvBRCA1; with germline BRCA2 mutation: OvBRCA2) were infected with Sendai virus vectors carrying three immortalization genes (Bmi-1, hTERT, and SV40T). The immunoreactivity to anti-epithelial cellular adhesion molecule (EpCAM) antibodies in each cell line and cells after 25 passages was confirmed using flow cytometry. Chromosomes were identified and karyotyped to detect numerical and structural abnormalities. Total RNA extracted from the cells was subjected to human transcriptome sequencing. Highly expressed genes in each cell line were confirmed using real-time polymerase chain reaction. Immortalization techniques allowed 25 or more passages of Ovn, OvBRCA1, and OvBRCA2 cells. No anti-EpCAM antibody reactions were observed in primary cultures or after long-term passages of each cell line. Structural abnormalities in the chromosomes were observed in each cell line; however, the abnormal chromosomes were successfully separated from the normal structures via cloning. Only normal cells from each cell line were cloned. MMP1, CCL2, and PAPPA were more predominantly expressed in OvBRCA1 and OvBRCA2 cells than in Ovn cells. Immortalized ovarian cells derived from patients with germline BRCA1 or BRCA2 mutations showed substantially higher MMP1 expression than normal ovarian cells. However, the findings need to be validated in the future.

  5. Characterization of human anti-EpCAM antibodies for developing an antibody-drug conjugate. International-journal Peer-reviewed

    Hiroyuki Satofuka, Yayan Wang, Kyotaro Yamazaki, Shusei Hamamichi, Takeshi Fukuhara, Abdur Rafique, Nana Osako, Iori Kanazawa, Takeshi Endo, Naomi Miyake, Kazuhisa Honma, Yuichi Nagashima, Genki Hichiwa, Kazuto Shimoya, Satoshi Abe, Takashi Moriwaki, Yasufumi Murakami, Xu Gao, Hiroyuki Kugoh, Mitsuo Oshimura, Yuji Ito, Yasuhiro Kazuki

    Scientific reports　13　(1)　4225-4225　2023/03/14

    DOI： 10.1038/s41598-023-31263-x 　

    More details Close

    We previously generated fully human antibody-producing TC-mAb mice for obtaining potential therapeutic monoclonal antibodies (mAbs). In this study, we investigated 377 clones of fully human mAbs against a tumor antigen, epithelial cell adhesion molecule (EpCAM), to determine their antigen binding properties. We revealed that a wide variety of mAbs against EpCAM can be obtained from TC-mAb mice by the combination of epitope mapping analysis of mAbs to EpCAM and native conformational recognition analysis. Analysis of 72 mAbs reacting with the native form of EpCAM indicated that the EpCL region (amino acids 24-80) is more antigenic than the EpRE region (81-265), consistent with numerous previous studies. To evaluate the potential of mAbs against antibody-drug conjugates, mAbs were directly labeled with DM1, a maytansine derivative, using an affinity peptide-based chemical conjugation (CCAP) method. The cytotoxicity of the conjugates against a human colon cancer cell line could be clearly detected with high-affinity as well as low-affinity mAbs by the CCAP method, suggesting the advantage of this method. Thus, this study demonstrated that TC-mAb mice can provide a wide variety of antibodies and revealed an effective way of identifying candidates for fully human ADC therapeutics.

Misc. 25

  1. 染色体工学技術応用(13):完全ヒト抗体κ型・λ型共発現マウスの解析

    増田優彩菜, 下谷和人, 森脇崇史, 森脇崇史, 岡田茜, 阿部智志, 香月康宏, 香月康宏, 香月康宏, 香月康宏

    日本分子生物学会年会プログラム・要旨集(Web)　48th　2025

  2. 臓器選択的mRNA-LNP送達が免疫応答に与える影響の基礎的検討

    赤羽祐哉, 下谷和人, 田中浩揮, 秋田英万

    日本分子生物学会年会プログラム・要旨集(Web)　48th　2025

  3. Isolation of Synthetic Human Polyclonal Antibodies Against SARS-CoV-2 via Mammalian Display

    渡辺新大, 福島隆斗, 安倍麻里奈, 宇野愛海, 宇野佳奈, 平塚正治, 下谷和人, 森脇崇史, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸, 冨塚一磨

    日本抗体学会学術大会プログラム・抄録集(Web)　4th　2025

  4. Construction of a CHO cell line for mammalian display enabling high-level expression of human antibodies through single-copy insertion of the Express Hu-mAb system (4) expression cassette

    木村香絵, 福島隆斗, 渡辺新大, 宇野愛海, 宇野佳奈, 平塚正治, 下谷和人, 森脇崇史, 金井亨輔, 田中浩揮, 景山誠二, 香月康宏, 末次正幸, 秋田英万, 冨塚一磨

    日本抗体学会学術大会プログラム・抄録集(Web)　4th　2025

  5. Express Hu-mAb System (1) Rapid generation of human neutralizing antibodies via mRNA-LNP immunization of fully human antibody producing mouse model

    濱道修生, 田中浩揮, 金井亨輔, 宇野愛海, 下谷和人, 福島隆斗, 森脇崇史, 森脇崇史, 景山誠二, 冨塚一磨, 秋田英万, 香月康宏, 香月康宏

    日本抗体学会学術大会プログラム・抄録集(Web)　4th　2025

  6. Express Hu-mAb System (2): Acquisition of anti-SARS-CoV-2 human monoclonal antibodies by Mammalian display method

    福島隆斗, 安倍麻莉奈, 宇野愛海, 宇野佳奈, 石津由紀, 渡辺新大, 平塚正治, 下谷和人, 森脇崇史, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸, 冨塚一磨

    日本抗体学会学術大会プログラム・抄録集(Web)　4th　2025

  7. 染色体工学技術応用(11):染色体工学技術を用いたヒトλ型抗体産生マウスの作製と解析

    下谷和人, 森脇崇史, 森脇崇史, 増田優彩菜, 馬場重典, 岡田茜, 香月加奈子, 阿部智志, 香月康宏, 香月康宏, 香月康宏, 香月康宏

    日本分子生物学会年会プログラム・要旨集(Web)　47th　2024

  8. Express Hu-mAbシステム(7)Mammalian display法による抗SARS-CoV-2合成ヒトポリクローナル抗体作製

    安倍麻莉奈, 福島隆斗, 宇野愛海, 石津由紀, 渡辺新大, 平塚正治, 下谷和人, 森脇崇史, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸, 冨塚一磨

    日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024

  9. Express Hu-mAb System (5) Development of a mammalian display antibody library derived from SARS-CoV-2 human antibody-producing mice

    宇野愛海, 安倍麻莉奈, 福島隆斗, 渡辺新大, 石津由紀, 平塚正治, 下谷和人, 森脇崇史, 濱道修生, 金井亨輔, 景山誠二, 末次正幸, 香月康宏, 冨塚一磨

    日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024

  10. mRNA-based antibody delivery into the body

    原田純希, 田中浩揮, 下谷和人, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 香月康宏, 香月康宏, 冨塚一磨, 秋田英万

    日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024

  11. Express Humabシステム(3)mRNAワクチンを用いたTc-mAbマウスへの免疫

    西尾一真, 田中浩揮, アニンディタ ジェシカ, 下谷和人, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 香月康宏, 香月康宏, 冨塚一磨, 秋田英万

    日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024

  12. Express Hu-mAb System (4) Rapid antibody generation by analysis of the single cell repertoire of fully human antibody producing mice

    下谷和人, 濱道修生, 金井亨輔, 福島隆斗, 宇野愛海, 景山誠二, 冨塚一磨, 香月康宏, 香月康宏

    日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024

  13. Express Hu-mAb System (2) Efficient procedure for immunization of fully human antibody producing mouse for rapid generation of broadly neutralizing antibody

    濱道修生, 金井亨輔, 下谷和人, 上山晟史, 森脇崇史, 森脇崇史, 田村友和, 田村友和, 田村友和, 宇野愛海, 福原崇介, 福原崇介, 福原崇介, 景山誠二, 冨塚一磨, 香月康宏, 香月康宏

    日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024

  14. Express Hu-mAb System (6) Acquisition of anti-SARS-CoV-2 human monoclonal antibody by Mammalian display method

    福島隆斗, 安倍麻莉奈, 宇野愛海, 宇野佳奈, 石津由紀, 渡辺新大, 平塚正治, 下谷和人, 森脇崇史, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸, 冨塚一磨

    日本抗体学会学術大会プログラム・抄録集(Web)　3rd　2024

  15. 染色体工学技術を用いたヒト抗体重鎖・λ軽鎖遺伝子全長を保持する完全ヒト抗体産生マウスの開発

    下谷和人, 馬場重典, 森脇崇史, 森脇崇史, 阿部智志, 岡田茜, 香月加奈子, 香月康宏, 香月康宏, 香月康宏, 香月康宏

    日本実験動物学会総会講演要旨集(Web)　71st　2024

  16. Fully human antibody-producing mice as a humanized model mouse.

    下谷和人, 飛知和弦輝, 香月康宏, 香月康宏, 香月康宏

    月刊臨床免疫・アレルギー科　80　(6)　696-701　2023/12

    Publisher: 東京 : 科学評論社

    ISSN： 1881-1930

  17. 染色体工学技術を用いたヒト抗体重鎖・λ軽鎖遺伝子全長を保持する完全ヒト抗体産生マウスの開発

    下谷和人, 森脇崇史, 森脇崇史, 阿部智志, 岡田茜, 香月加奈子, 濱道修生, 香月康宏, 香月康宏, 香月康宏

    日本実験動物学会総会講演要旨集(Web)　70th　2023

  18. 染色体工学技術の抗体研究への応用(1)ヒト抗体重鎖・λ軽鎖遺伝子全長を保持する完全ヒト抗体産生マウスの開発

    下谷和人, 馬場重典, 森脇崇史, 森脇崇史, 阿部智志, 岡田茜, 香月加奈子, 香月康宏, 香月康宏, 香月康宏

    日本抗体学会学術大会プログラム・抄録集(Web)　2nd　2023

  19. 染色体工学技術の抗体研究への応用(9)mammalian display法による抗SARS-Cov-2合成ヒトポリクローナル抗体取得

    安倍麻莉奈, 福島隆斗, 石津由紀, 宇野愛海, 平塚正治, 下谷和人, 森脇崇史, 里深博幸, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸, 冨塚一磨

    日本抗体学会学術大会プログラム・抄録集(Web)　2nd　2023

  20. 染色体工学技術の抗体研究への応用(10)Mammalian display法による抗SARS-CoV-2合成ヒトモノクローナル抗体取得法の開発

    宇野愛海, 安倍麻莉奈, 福島隆斗, 石津由紀, 冨塚一磨, 平塚正治, 下谷和人, 森脇崇史, 里深博幸, 濱道修生, 金井亨輔, 景山誠二, 香月康宏, 末次正幸

    日本抗体学会学術大会プログラム・抄録集(Web)　2nd　2023

  21. Application of chromosome engineering technology (10): Development of human IgH/Igλ antibody-producing mice by using artificial chromosome.

    下谷和人, 森脇崇史, 森脇崇史, 阿部智志, 岡田茜, 香月加奈子, 香月康宏, 香月康宏, 香月康宏

    日本分子生物学会年会プログラム・要旨集(Web)　45th　2022

  22. 染色体工学技術の抗体研究への応用(10)免疫系ヒト化動物を活用した抗感染症ヒト抗体創成基盤の確立

    冨塚一磨, 宇野愛海, 香月康宏, 香月康宏, 濱道修生, 下谷和人, 末次正幸, 田中浩揮, 秋田英万

    日本抗体学会学術大会プログラム・抄録集(Web)　1st　2022

  23. 染色体工学技術の抗体研究への応用(11)完全ヒト抗体産生マウスを用いた迅速なヒト抗体作製技術の開発

    下谷和人, 濱道修生, 里深博幸, 大安知里, 遠藤猛, 金澤伊織, 森本佳世子, 高山悠, 嵩原昇子, 押村光雄, 富塚一磨, 香月康宏, 香月康宏

    日本抗体学会学術大会プログラム・抄録集(Web)　1st　2022

  24. Application of chromosome engineering technology (9): Generation of internalizing monoclonal antibodies using fully human antibody-producing mice and their comprehensive analyses by cytotoxicity-based assay systems

    下谷和人, 下谷和人, 里深博幸, 貞包和樹, 貞包和樹, 飛知和弦輝, 飛知和弦輝, 香月康宏, 香月康宏, 香月康宏

    日本分子生物学会年会プログラム・要旨集(Web)　44th　2021

  25. Application of chromosome engineering technology (10): Development of a simple technique for producing monoclonal antibodies using protein probes

    貞包和樹, 貞包和樹, 里深博幸, 田中博志, 田中満里愛, 森本佳世子, 下谷和人, 下谷和人, 飛知和弦輝, 飛知和弦輝, 栗原靖之, 押村光雄, 香月康宏, 香月康宏

    日本分子生物学会年会プログラム・要旨集(Web)　44th　2021

Show all ︎Show first 5

Presentations 1

  1. 染色体工学技術を用いたヒト抗体重鎖・λ軽鎖遺伝子全長を保持する完全ヒト抗体産生マウスの開発

    下谷和人, 馬場重典, 森脇崇史, 阿部智志, 岡田茜, 香月加奈子, 香月康宏

    日本実験動物学会第70回定期大会　2024/05

Research Projects 1

  1. mRNA免疫技術を活用した抗体取得プロセス開発

    下谷 和人

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 研究活動スタート支援

    Institution: 東北大学

    2025/07/31 - 2027/03/31